Share
0 0 0 0

For Beaten-Down Maker of Alzheimer's Drug, Good Enough Will Do

April 25, 2024



In-line sales for Alzheimer’s drug Leqembi and a beat for rare-disease drug Skyclarys has Wall Street giving Biogen another chance.



Source link